Katanosin B

Drug Profile

Katanosin B

Latest Information Update: 09 Feb 2006

Price : $50

At a glance

  • Originator Unknown
  • Developer Shionogi; St. Marianna University School of Medicine; Toho University School of Medicine
  • Class Depsipeptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 09 Feb 2006 No development reported - Preclinical for Bacterial infections in Japan (unspecified route)
  • 15 Nov 1999 Preclinical development for Bacterial infections in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top